ImmunityBio Securities Fight Intensifies After FDA Rebuke Over Anktiva Claims

Overview

• Plaintiff firms issued fresh notices this week urging ImmunityBio investors to seek lead‑plaintiff status by May 26, 2026.
• The case, Douglas v. ImmunityBio, is filed in the Central District of California and covers purchases from January 19 to March 24, 2026.
• The lawsuit follows an FDA Warning Letter that found a TV ad and a podcast about Anktiva were false or misleading by suggesting it could cure or prevent all cancer.
• The FDA also said the promotions left out Anktiva’s full approved use, which is only with BCG for a type of non‑muscle invasive bladder cancer.
• Following reports on March 24, 2026 about the FDA letter, shares fell about 21% and the complaint names ImmunityBio and Executive Chairman Dr. Patrick Soon‑Shiong.